Plain-English translation of NCT06627556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called to see how safe it is and how the body processes it. Researchers will give healthy volunteers gradually increasing doses of the medication — first as single doses, then as daily doses over a week — to understand any side effects and how the body handles the treatment.
Before this medication can be tested in patients with ulcerative colitis, researchers need to make sure it is safe and that the body can tolerate it. This early safety testing in healthy people is a required first step before moving forward to test the medication in actual patients.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as a single dose or once daily for seven days, depending on which group you are assigned to. The trial involves multiple visits where researchers will check your health, take blood samples, and monitor how you feel. Your participation will last several weeks, during which you'll need to fast before some doses and keep detailed records of any side effects you experience.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Jiangsu Carephar Pharmaceutical Co., Ltd.
Enrollment target
~64 participants
Started
September 2024
Primary completion
February 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr. Ofer Gonen
Jiangsu Carephar Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.